The gold standard for diagnosing familial hypercholesterolemia (FH) is identification of a causative pathogenic mutation. However, genetic testing is expensive and not widely available.
F amilial hypercholesterolemia (FH) is a codominantly inherited disorder resulting in elevated low-density lipoprotein (LDL) cholesterol concentration and increased risk of premature atherosclerotic cardiovascular disease (ASCVD) (1) . FH is primarily caused by mutations in the LDL receptor (LDLR), and less commonly by mutations in apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes (2) . The prevalence of heterozygous FH is estimated to be 1 in 250 in unselected community populations (3) (4) (5) . Although genetic testing is the reference standard for diagnosing FH and has great value in risk assessment and cascade screening, it is expensive and not widely available (6) . Deciding whether to undertake a genetic test in patients with phenotypic FH referred to a clinic is a key consideration.
The clinical diagnosis of FH is based on identifying a personal and family history of premature coronary artery disease (CAD), tendon xanthomata, corneal arcus, and elevated LDL cholesterol (7) (8) (9) . However, there is no standardized phenotypic diagnosis of FH (10) . The most commonly recommended diagnostic tools include the Dutch Lipid Clinic Network (DLCN), the Simon Broome (SB), and Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria (7) (8) (9) . However, a detailed family history and physical stigmata required by the DLCN and SB criteria may be difficult to elicit. A simplified diagnosis of FH, based on LDL cholesterol level and family history of elevated LDL cholesterol or premature CAD, was recently proposed by the American Heart Association (AHA) (11) .
We previously reported on the characteristics of patients with FH in a service for lipid disorders in Western Australia (6, 12) . We now compare the diagnostic validity of the aforementioned clinical tools in discriminating between the presence and absence of a pathogenic gene variant causative of FH. We thereby aimed to identify the optimal phenotype for predicting a mutation and how best to use genetic testing for FH in the clinic.
Materials and Methods

Study design
A cross-sectional comparison was undertaken of unrelated patients aged $18 years with or without a recognized mutation causative of FH. The care of these patients has been previously described (6, 12) . In brief, adult patients with suspected FH were recruited via referral from general practice, coronary care, or other specialists. Reasons for suspecting FH were generally an elevated plasma LDL cholesterol with a family or personal history of CAD. Patients were evaluated by specialist physicians at the Lipid Disorders Clinic at Royal Perth Hospital (Perth, Western Australia); if the diagnosis was at least possible FH, they were genetically tested after appropriate counseling and consent. The study was approved by the Royal Perth Hospital Human Research Ethics Committee.
Clinical data
Age, gender, history of coronary and other vascular disease, diabetes, hypertension, smoking status, examination findings (weight, height, blood pressure), and medications were recorded. The definitions of CAD, diabetes, hypertension, and obesity were previously described (6, 12) .
Phenotypic diagnosis of FH
Details were obtained of family and personal history of hypercholesterolemia, premature coronary or vascular disease, tendon xanthomata (bilateral, subcutaneous nodules on Achilles tendons or at ligamentous insertions), and corneal arcus; pretreatment plasma LDL cholesterol concentration was recorded. Where a pretreatment plasma lipid profile was not available (25% of the cohort), a correction that accounted for type, dose, and frequency of statins and use of ezetimibe (Supplemental Table 1 ) was used to estimate pretreatment LDL cholesterol concentrations (13) . Patients were classified phenotypically, using the same individual variable, according to the DLCN, SB, MEDPED, and AHA diagnostic criteria (Supplemental Table 2 ) (7-11). Because ;30% of Lp(a) mass is cholesterol (14) , in subsidiary analyses LDL cholesterol was also adjusted for the cholesterol content of Lp(a) by subtracting 30% of total Lp(a) mass from the measured LDL cholesterol concentration.
Genetic diagnosis of FH
The diagnosis of FH was based on the presence of a pathogenic gene variant. DNA extraction, multiplex ligationdependent probe amplification, and Sanger sequencing of the 18 exons of the LDLR, exon 7 of PCSK9, and part of APOB exons 26 and 29 were performed, as previously described (6) . In 10% of patients, genetic testing was based on next-generation sequencing (NGS), performed by Ion Torrent sequencing using a TargetSeq (Life Technologies, Waltham, MA) custom capture panel of lipid genes and polymorphisms, derived from LipidSEquation (15) . Mutation detection rates with NGS (29%) and Sanger sequencing (30%) were not significantly different. Multiplex ligation-dependent probe amplification was performed in all patients with DLCN probable or definite FH in whom Sanger sequencing or NGS did not identify a mutation.
Laboratory analyses
Venous blood samples were collected during clinic visits. Plasma cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride concentrations were determined by standard enzymatic methods. LDL cholesterol was calculated by the Friedewald Equation (16) , but in patients with plasma triglyceride .4.5 mmol/L, a direct LDL cholesterol assay was used. Total apoB and Lp(a) [Quantia Lp(a) assay and standards] were determined by immunoassay (Abbott Laboratories, Abbott Park, IL), with interassay coefficient of variation of ,5%.
Statistical analyses
All data were analyzed using SPSS (version 21, Chicago, IL). Differences in clinical characteristics between FH index cases with and without a pathogenic mutation (LDLR, APOB, and PCSK9) were tested with x 2 or independent t tests. Skewed variables, including plasma triglyceride and Lp(a) concentrations, were log-transformed. Logistic regression was used to assess prediction of a mutation. The discriminant value of plasma LDL cholesterol concentration and the DLCN score in predicting a mutation were depicted using receiver operator characteristic (ROC) area under the curve (AUC). Cohen's k coefficient was used to measure the phenotypic agreement between DLCN, SB, MEDPED, and AHA criteria. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and Youden index were used to compare the diagnostic value of the clinical tools and their components in predicting a mutation. Improvement in prediction of a mutation with individual variable relative to the DLCN and SB definitions was estimated as differences between the AUCs and compared using C-statistics. Statistical significance was defined at the 5% level.
Results
A total of 931 adult patients with at least possible FH according to the DLCN criterion (score $3) was genetically screened for a causative mutation for FH from March 2007 to September 2017. Patients with homozygous FH, compound or double heterozygous FH (n = 6), LDLR or APOB variants of uncertain significance (n = 30), pathogenic or uncertain ABCG5/8 variants (n = 5), or those with frank secondary causes of hypercholesterolemia (n = 5) were excluded from the analysis. Of the remaining 885 index cases, 267 (30%) of the screened cases had a pathogenic FH-causing mutation: 237 were found to have mutation in the LDLR gene (60% missense, 20% nonsense/frameshift, 11% splice, 8% large deletion/duplication, and 1% promoter variants), whereas others were heterozygous for APOB (n = 25), PCSK9 (n = 3), and APOE p.Leu167del (n = 2) mutations.
The characteristics of the 885 patients with (M + ) and without (M 2 ) a mutation are shown in Table 1 . M + individuals were older, and had a higher frequency of non-Caucasian origin, tendon xanthomata, and corneal arcus (P , 0.01 for all) than M 2 patients. There were no significant differences in the proportion of men, smokers, In univariate regression analysis (Table 2) , family history of ASCVD (premature CAD and/or cerebral/ peripheral vascular disease) or elevated LDL cholesterol and presence of tendon xanthomata, corneal arcus, and elevated LDL cholesterol were all significant predictors of a mutation [odds ratio (OR) range 3.00 to 27.0, P , 0.001 for all]. Using the DLCN criteria, the ORs for an FH-causing mutation were 9.47 [95% confidence interval (CI) 6.81 to 13.2] and 8.58 (5.40 to 13.6) for definite and for probable/definite FH, respectively. The ORs for SB definite, possible/definite FH, MEDPED, and AHA criteria were 11.7 (7.15 to 19.1), 7.79 (4.57 to 13.3), 10.5 (7.48 to 14.9), and 4.67 (3.07 to 7.09), respectively. Age and ethnicity were also significant predictors of a mutation (OR 0.977, 95% CI 0.966 to 0.987 and 2.02, 95% CI 1.32 to 3.09, respectively); i.e., mutations were more likely in younger and non-Caucasian patients. As seen in Table 2 , family history, physical stigmata, and elevated LDL cholesterol remained independent predictors of the presence of a mutation in multivariate regression models. In stepwise regression analysis, including tendon xanthomata, family history of physical stigmata, and the DLCN definite criteria, elevated LDL cholesterol ($8.5 mmol/L) was the best predictor of the presence of a mutation (b-coefficient 2.22, standard error 0.351). The b-coefficients for tendon xanthomata, family history of physical stigmata, and an independent predictor of the presence of a mutation in the multivariate regression models. Inclusion of age, gender, and ethnicity as independent variables also did not alter the significance of the aforementioned variables in detecting a mutation. Table 3 shows the concordance and discordance rates between the four clinical diagnostic tools. There was a moderate agreement between DLCN and SB definite (8=0.455), with an overall discordance rate of 19%. However, there was a poor agreement between DLCN probable/definite and MEDPED criteria (8=0.120, concordance rate 67%, discordance rate 33%), between SB possible/definite and MEDPED criteria (8=0.185, concordance rate 56%, discordance rate 44%), and between the AHA criteria and DLCN definite (8=0.120, concordance rate 49%, discordance rate 51%), SB definite FH (8=0.028, concordance rate 36%, discordance rate 64%), and MEDPED criteria (8=0.176, concordance rate 56%, discordance rate 44%). The k coefficient between b Positives and negatives refer to outcomes by the former phenotypic diagnostic category.
the DLCN probable/definite and the SB possible/definite and AHA criteria was 0.378 and 0.338, respectively, and between SB definite and MEDPED criteria 0.205, reflecting fair agreement between them. There was a very good agreement between the SB possible/definite and AHA criteria (8=0.908, concordance rate 99%, discordance rate 1%). The ROC curve for LDL cholesterol and DLCN score in predicting an FH-causing mutation is shown in Supplemental Fig. 1 . The higher the LDL cholesterol levels and DLCN score, the greater the specificity and the lower the sensitivity in detecting a mutation. The ROC curve for LDL cholesterol (AUC 0.835; 95% CI 0.806 to 0.865) and for DLCN score (AUC 0.816; 95% CI 0.784 to 0.847) was comparable in detecting a mutation (difference between ROC areas 0.020; 95% CI 20.001 to 0.048; P = 0.164). The AUC for LDL cholesterol, after adjusting for Lp(a) cholesterol, in detecting a mutation was 0.841 (95% CI 0.812 to 0.870), which was also not significantly different from that for DLCN score as a continuous variable (difference between ROC areas 0.011; 95% CI 20.017 to 0.040; P = 0.453). Table 4 shows the sensitivity, specificity, PPV, NPV, Youden index, and AUC for different diagnostic criteria in detecting an FH-causing mutation. A family history of physical stigmata, the presence of tendon xanthomata, and a LDL cholesterol $8.5 mmol/L had high specificities (.95% for all), but relatively low sensitivities (range 31.1% to 36.7%) in detecting a mutation. A family history of premature CAD or hypercholesterolemia had high sensitivity (90.2%), but low specificity (24.4%) in detecting a mutation. Lower plasma LDL cholesterol concentrations were more sensitive (from 36.7% to 98.9%) but less specific (from 97.9% to 14.7%) in detecting a mutation. The highest Youden index among the individual diagnostic components was 0.485 with a LDL cholesterol $6.5 mmol/L.
With the composite diagnostic criteria, Table 4 also shows that SB definite FH had a higher specificity (96.3%) but lower sensitivity (31.1%) in detecting a mutation than DLCN definite FH (specificity 83.5%, sensitivity 65.2%) and MEDPED criteria (specificity 88.9%, sensitivity 56.8%). However, the DLCN definite FH (Youden index 0.487) and MEDPED criteria (Youden index 0.457) had a better balance between sensitivity and specificity than the SB definite (Youden index 0.274) in detecting a mutation. Although the AHA criteria had a high sensitivity (89.1%), its specificity (36.2%) was lower compared with DLCN definite, SB definite, or MEDPED criteria. The Youden indices for the composite were in decreasing order: DLCN definite, MEDPED criteria, DLCN probable/definite, SB definite, SB possible/definite, and AHA criteria.
With reference to a DLCN definite diagnosis, the AUCs were significantly less (P , 0.05 for all) with family history of ASCVD (or elevated LDL cholesterol), family and personal history of physical stigmata, personal history of ASCVD, elevated LDL cholesterol ($5.0 mmol/L or $8.5 mmol/L), DLCN probable/definite FH, SB possible/ definite FH, and AHA criteria (AUC range 20.067 to 20.239). With reference to a SB definite diagnosis, the AUCs were significantly less (P , 0.05 for all) with family history of ASCVD (or elevated LDL cholesterol), personal history of ASCVD, corneal arcus, and elevated LDL cholesterol $5.0 mmol/L (AUC range 20.069 
Discussion
In a large sample of patients referred to a specialist clinic, we demonstrated that the DLCN, SB, and MEDPED phenotypes were valid predictors of an FH-causing mutation, the AHA criteria having the lowest diagnostic specificity. Among individual phenotypic components, the pretreatment LDL cholesterol and presence of tendon xanthomata afforded the best discriminant value in predicting a mutation that overall matched the DLCN definite, SB definite, and MEDPED criteria. The concordance between these phenotypic tools for FH was, however, only moderate. Several studies have examined the relationship between clinical diagnostic tools and genetically defined FH. Damgaard et al. (17) reported that the DLCN and SB criteria were comparably effective in identifying most carriers of an FH-causing mutation, with specificities .85%, but sensitivities of ,45%; the discriminant value of individual diagnostic components was not investigated. The diagnostic yield of the DLCN and SB criteria in predicting the common FH-causing mutations was later confirmed in a larger community population, but there was limited information on family history and no records of physical stigmata of FH (4). Haralambos et al. (13) reported on the value of a modified DLCN criteria in predicting FH-causing mutations in Wales, but the findings were limited by lack of genetic data in individuals with lower DLCN score. Silva et al. (18) found that the DLCN score was a significant predictor of a mutation, but SB diagnostic criteria were not examined. Civeira et al. (19) also reported that the MEDPED criteria had high sensitivity and specificity in predicting a mutation in Spanish patients, but tendon xanthomata and age-adjusted LDL cholesterol were the most significant predictors of a mutation. We extend previous reports by comparing the discriminant value of different phenotypic criteria in predicting an FH-causing mutation among referrals to a specialist clinic.
That a higher proportion of M + than M 2 patients in our study fulfilled a phenotypic diagnosis of FH according to the DLCN definite, SB definite, MEDPED, and AHA criteria was anticipated. Tendon xanthomata and markedly elevated LDL cholesterol are classical hallmarks of FH (7) (8) (9) 11) . Consistent with previous studies (18, 19, 21) , the presence of tendon xanthomata and/or corneal arcus in the potential index cases was an independent predictor of the presence of an FH-causing mutation (Table 2) . Likewise, a pretreatment LDL cholesterol .4.9 mmol/L was confirmed as an independent predictor of a mutation. Given that tendon xanthomata and elevated LDL cholesterol are major criteria for the DLCN and SB diagnostic tools (7, 9) , it was anticipated that these phenotypic components were highly predictive of a mutation. Although the AHA tool was also predictive of a mutation, its specificity and PPV were significantly less than DLCN and SB definite and MEDPED criteria. In agreement with Civeira et al. (19) , we found that a history of premature CAD was not a significant predictor of a mutation. This accords with recent understanding that the major causes of premature CAD are due to multigenic and adverse lifestyle factors. As suggested elsewhere, familial combined hyperlipidemia and common hypercholesterolemia with elevated Lp(a) are frequent phenocopies of FH (22). Although we studied referrals to a specialist clinic, ;30% of patients with a definite phenotypic FH by DLCN and SB criteria did not have an FH-causing mutation. This points to polygenic hypercholesterolemia (attributed to common, small-effect LDL cholesterol-raising alleles), or unrecognized genetic causes of autosomal dominant hypercholesterolemia (23, 24) . Conversely, .15% of patients with a mutation were not identified by a DLCN or SB definite diagnosis. This suggests less severe FH phenotypes associated with pathogenic LDLR variants causing less LDL-receptor dysfunction, reduced genetic penetrance, and/or coinheritance of protective genes (25) . Earlier detection and treatment with statins can also modify phenotypic FH (26) . The phenotypic diagnosis of FH appears more dependent on the pretreatment LDL cholesterol than on other clinical features of FH, consistent with the earlier MEDPED recommendations (8), although clinical stigmata allow greater refinement of the diagnosis (8, 27) .
The strength of the study was the use of wellstandardized, comprehensive criteria for characterizing patients. However, there were limitations. The sample was predominantly Caucasian, but reflected the ethnic distribution of the Australian population. That the likelihood of an FH-causing mutation was increased in non-Caucasians reflects higher specificity in this group of applying Caucasian criteria. The diagnosis of FH in children based on LDL cholesterol was not examined, but is reviewed elsewhere (28) . Because of ascertainment bias, our results may have limited applicability to the community diagnosis of FH, but our conclusions may be valuable when applied to targeted screening of electronic health records for FH in primary care (29) . Approximately 25% of our patients were on cholesterol-lowering medication, and pretreatment LDL cholesterol was derived using adjustments that might not have fully reflected true values (13) . Testing for cholesterol allelic gene scores might have helped identify patients with isolated polygenic hypercholesterolemia (24) .
Implications
The reference diagnosis of FH is the identification of a pathogenic mutation that affects the clearance of LDL via the LDL-receptor pathway (1, 2) . Genetic testing may be used to predict ASCVD risk (19) , but is currently expensive and not widely available. Moreover, not all patients consent to genetic testing owing to personal preferences and potential discrimination by employers and insurers (3, 5, 11, 25) . Knowledge of the phenotypic predictors of a mutation may be useful for improving the accuracy of diagnosis where genetic testing is not available, or not consented to, and for rationing genetic testing where resources are limited.
With rising awareness of FH in primary care, an increasing number of patients will be referred to specialist clinics for confirmation of the diagnosis. Because of limited resources, it may be necessary to phenotypically identify patients who are very likely to have FH in whom genetic confirmation may be less valuable (unless combined with cascade screening), patients with an intermediate clinical likelihood in whom genetic testing may be particularly useful, and patients with low likelihood in whom genetic testing could be wasteful. Cascade screening for FH using LDL cholesterol and genetic testing is potentially cost effective (27, 30, 31) . Phenotypic cascade testing from index cases with a definite clinical diagnosis is also intuitively more cost effective than from index cases with lesser probabilities of FH. Hence, genetic testing of index cases with an intermediate probability of FH may offer an effective use of laboratory resources in the context of cascade testing.
Based on our results, Fig. 1 shows the application of the four phenotypic diagnostic tools to the detection of a mutation and to enable decision regarding genetic testing in patients referred to clinics. In this scheme, genetic testing could be recommended in patients with an intermediate probability of having a mutation and could be considered in patients with a low phenotypic probability in whom the clinical suspicion of FH is high. A caveat is that although prediction of a mutation appears statistically comparable among DLCN, SB, and MEDPED criteria, the phenotypic classification of patients can be discordant ( Table 3 ).
Given that information on individual family members is not always available, a simpler scheme shown in Fig. 2 uses the pretreatment LDL cholesterol and presence of tendon xanthomata in potential index cases to predict the likelihood of a mutation and value of genetic testing. Use of pretreatment LDL cholesterol as the primary criterion accords with earlier MEDPED recommendations (8) and is useful for identifying patients with intermediate likelihood of FH in whom genetic confirmation is required. Inclusion of tendon xanthomata as a second criterion further improves the specificity of the diagnosis of FH. AHA diagnostic tools in predicting the likelihood of an FH-causing mutation and assisting decisions on whether to undertake genetic testing. Genetic testing is arbitrarily not routinely recommended where probability of a mutation is ,15%, is recommended when the probability of a mutation is 15% to 60%, and is optional when the probability of a mutation .60%.
In adult patients referred to a specialist lipid clinic, prediction of an FH-causing mutation, or the decision to request a genetic test, could simply be based on the pretreatment LDL cholesterol and presence of a personal (or family) history of tendon xanthomata. Whereas florid tendon xanthomata are currently less frequent among heterozygous FH (32) , their earlier detection may be enhanced with ultrasonography (33) . This may provide a more standardized approach to the diagnosis of FH and overcome the notable discordance between DLCN and SB clinical diagnostic criteria. Country-specific LDL cholesterol levels should replace the original MEDPED criteria (8, 27) . Services with requisite laboratory and clinical resources may elect to genetically test all patients referred with a putative diagnosis of FH, but the cost effectiveness of this policy remains to be evaluated.
